The Indian government has officially announced a cap on trade margins for 137 anti-cancer drugs, a move intended to make life-saving oncology treatments more affordable for the public. By limiting the profit margins that distributors and retailers can add to these medications, the government seeks to curb the high out-of-pocket expenses often faced by cancer patients.

While the specific mechanism of the cap involves regulating the markup between the manufacturer's price and the final retail price, the policy is part of a broader effort by the National Pharmaceutical Pricing Authority (NPPA) to control the cost of essential medicines. This intervention follows ongoing concerns regarding the high cost of specialized cancer care in India, where medication costs often represent a significant portion of a patient's financial burden. The government has indicated that this measure is designed to ensure that the benefits of price regulation are passed directly to the consumer, rather than being absorbed by intermediaries in the supply chain. The policy applies to a wide range of anti-cancer drugs, reflecting an attempt to standardize pricing across the oncology sector.